Method of diagnosis and treatment of tumors using high intensity focused ultrasound
View Patent ↗A method of diagnosis and treatment of tumors using High Intensity Focused Ultrasound is provided. The method of diagnosing the presence of a tumor in a patient comprises the steps of subjecting a tumor to high intensity focused ultrasound (HIFU) to cause the tumor cells to release cellular material and evaluating the cellular material for a tumor marker. The method of treating a tumor in a patient can also comprise the step of subjecting a tumor to high intensity focused ultrasound (HIFU) to provoke an immune response.
1. A method of treating a tumor in a patient, the method comprising:
stimulating stem cells with cytokines to produce dendritic cells and thereby preparing the patient's immune system to be receptive to tumor antigens; and
subjecting a tumor to high intensity focused ultrasound (HIFU) that is applied continuously for a duration no longer than 20 seconds, wherein the application of HIFU causes release of cellular material from one or more cells of the tumor thereby provoking an immune response that encompasses some or all metastatic cells of the tumor.
2. The method of claim 1 , wherein the HIFU includes a high energy, high intensity focused ultrasound (HI-HIFU).
3. The method of claim 1 , wherein the HIFU includes a low energy, high intensity focused ultrasound (LO-HIFU).
4. The method of claim 1 , wherein the HIFU is administered as a combination of HI-HIFU and LO-HIFU.
5. The method of claim 1 , wherein the tumor is subjected to HIFU that is applied as a pulse with a pulse duration of about 1 to 100 milliseconds.
6. The method of claim 3 , wherein the tumor is subjected to LO-HIFU by moving a HIFU focus across a tumor.
7. The method of claim 2 , wherein the tumor is subjected to HI-HIFU that moves across a tumor.
8. The method of claim 1 , wherein the tumor is subjected to more than application of HIFU.
9. The method of claim 1 , wherein the HIFU causes necrosis of the tumor.
10. The method of claim 1 , wherein the HIFU does not cause necrosis of the tumor.
11. The method of claim 2 , wherein the HI-HIFU applies power in the amount of about 1.3 to 2.0 KW per cm 2 .
12. The method of claim 2 , wherein the HI-HIFU has an operating frequency of about 1.0 to 5.0 MHz.
13. The method of claim 2 , wherein the HI-HIFU has an operating frequency greater than about 20 KHz and less than about 100 MHz.
14. The method of claim 3 , wherein the LO-HIFU applies power in the amount of about 0.5 KW per cm 2 .
15. The method of claim 3 , wherein the LO-HIFU applies energy in the amount of about 0.01 to 3.0 KW-seconds per cm 2 .
16. The method of claim 3 , wherein the LO-HIFU operates with a pulse having a duration of about 0.01 to 1.0 seconds with pulse repetition frequencies of about 0.5 to 5.0 Hz.
17. The method of claim 3 , wherein the LO-HIFU operates with repetition frequencies of about 0.5 to 30.0 Hz.
18. The method of claim 7 , wherein the HI-HIFU operates with repetition frequencies of about 0.5 to 30.0 Hz.
19. The method of claim 1 , wherein the HIFU is applied in one of the following approaches: extracorporeal, infra cavity, percutaneous, robotic, laparoscopic, and directly on the tumor.
20. The method of claim 5 , wherein the frequency of the HIFU is greater than about 20 KHz and less than about 100 MHz.
21. The method of claim 1 , wherein the immune response is directed to diseased tissue other than the tumor subjected to the HIFU.
22. The method of claim 1 , wherein the immune response is enhanced by administering an immunomodulatory compound.
23. The method of claim 22 , wherein the administration of the immunomodulatory compound includes proving at least one immunomodulatory molecule.
24. The method of claim 23 wherein the immunomodulatory molecule is a cytokine.
25. The method of claim 24 , wherein the cytokine is a dendritic cell-stimulating cytokine.
26. The method of claim 24 , wherein the cytokine is selected from the group consisting of G-CSF and GM-CSF.
27. The method of claim 24 , wherein the cytokine is selected from the group consisting of chemokines, lymphokines and interleukins.
28. The method of claim 22 , wherein the administration of the immunomodulatory compound comprises delivering to the patient an effective amount of a composition that stimulates the immune system of the patient.
29. The method of claim 24 , wherein the cytokine is a T lymphocyte-stimulating cytokine.
30. The method of claim 27 , wherein the T lymphocyte-stimulating cytokine is IL-2 or IL-15.
31. The method of claim 23 , wherein the immunomodulatory molecule is CD40L.
32. The method of claim 23 , wherein the immunomodulatory molecule is a molecule is a chemokine.
33. The method of claim 23 , wherein the immunomodulatory molecule is a molecule that down-regulates regulatory T-cells.
34. The method of claim 33 , wherein the immunomodulatory molecule is an anti-CTLA4 antibody.
35. The method of claim 23 , wherein the immunomodulatory molecule is 4-1 BB ligand.
36. The method of claim 23 , wherein the immunomodulatory molecule is a CpG oligonucleotide.
37. The method of claim 23 , wherein the composition comprises an anti-tumor vaccine.
38. The method of claim 37 , wherein the vaccine comprises an autologous tumor cell vaccine.